BMI1 and glioma: This mechanism is active in glioma-initiating cells (GICs), suggesting that restoring ephrin-A5 signaling or targeting the Bmi1-ephrinA5 axis may represent a promising therapeutic strategy for Bmi1-overexpressing GBMs (Ricci et al., 2020).